We hypothesize that the COPD-associated chronic inflammatory microenvironment (e.g., elevated IL-6 or TNF-α levels) may impair the efficacy of EGFR-TKI therapy through activation of the JAK/STAT signaling pathway, a hypothesis requiring experimental validation. The gene discussed is IL6; the disease is chronic obstructive pulmonary disease.